Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236768 | 0.85 | GAA (0.36) | L3MBTL1KMT2AGAAMEN1 | |
| SCHEMBL2238051 | 0.85 | HDAC1 (0.37) | L3MBTL1KMT2AGAAMEN1HDAC4 | |
| SCHEMBL2238684 | 0.85 | CHRM1 (0.36) | L3MBTL1HDAC4 | |
| SCHEMBL2240153 | 0.83 | ALDH1A1 (0.39) | L3MBTL1KMT2AGAAMEN1 | |
| SCHEMBL2239265 | 0.82 | HDAC1 (0.39) | KMT2AMEN1 | |
| SCHEMBL2236534 | 0.82 | HDAC1 (0.38) | L3MBTL1NCOA3 | |
| SCHEMBL2238884 | 0.82 | POLB (0.36) | L3MBTL1KMT2AGAA | |
| SCHEMBL13935076 | 0.82 | L3MBTL1 (0.40) | L3MBTL1KMT2AGAAGPR119NCOA3 | |
| SCHEMBL2234755 | 0.81 | HDAC1 (0.35) | L3MBTL1 | |
| SCHEMBL2236865 | 0.81 | HDAC1 (0.37) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | ASTELLAS PHARMA INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | RECQL, DNA2, DHX35 | L3MBTL1 1740/4885KMT2A 1021/4885GAA 272/4885 |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | TK1, TYMP, RPL23 | L3MBTL1 3792/4885KMT2A 1065/4885GAA 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.